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Summary 
We have reported previously that activation of human umbilical  vein endothelial cells (HUVECs) 
through CD40, using a recombinant soluble form oftrimerized CD40 ligand, leads to induction 
of  E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule-1 
(ICAM-1). Here, we compare the effects of CD40 ligand with those of tumor necrosis factor 
(TNF) and interleukin 1 (IL-1). All three ligands induce transient increases in E-selectin (peak 4 h) 
and VCAM-1  (peak 8-24 h), as well as sustained increases in ICAM-1  (plateau 24 h). Quanti- 
tatively, TNF is more potent than 1L-1,  which is much more potent than CD40 ligand. The 
same  hierarchy is  observed for transcriptional  activation of an E-selectin promoter reporter 
gene construct in transiently transfected HUVECs. TNF and CD40 ligand each induced acti- 
vation  of the  transcription  factors NF-KB,  IRF-1,  and ATF-2/c-Jun,  measured by electro- 
phoretic mobility shift assays, but this response appeared quantitatively similar.  All three agents 
transiently (peak 30 rain) activatedJun NH2-terminal kinase (]NK), which has been implicated 
in transcription  of E-selectin through its  actions on ATF-2/c-Jun.  Activation of JNK again 
showed a hierarchy of potency (TNF> IL-I>> CD40 ligand),  although the time course of in- 
duction was similar for all three agents.  After 44 h ofpretreatment, TNF, IL-1, and CD40 li- 
gand each display homologous desensitization for reinduction of  surface expression of  E-selectin. 
A  similar pattern  of homologous desensitization for reactivation of JNK was  observed. We 
conclude that TNF, IL-1, and CD40 ligand all activate similar responses in ECs, and that ho- 
mologous desensitization of  JNK may explain the inability of individual cytokines to reinduce 
E-selectin expression. 
E 
ndothelial  cells  (ECs) 1  can  be  activated by cytokines 
such as TNF and IL-1 to express various adhesion mol- 
ecules that bind circulating leukocytes at sites  of local in- 
flammation (1).  For example, TNF- and IL-l-treated hu- 
man umbilical vein ECs (HUVECs) express E-selectin (also 
called CD62E, endothelial leukocyte adhesion molecule-I; 
2, 3), a receptor protein that mediates the initial tethering 
to, and rolling on, endothelium by neutrophils and certain 
other leukocytes during the early phase of acute inflamma- 
tion (4, 5).  Cytokine-treated ECs also express vascular cell 
~Abbreviations used in this paper: cRE, cAMP-responsive  element;  EC, en- 
dothelial cell; GST, glutathione S-transferase;  HUVEC, human umbilical 
vein EC; ICAM, intercellular  adhesion molecule;  .JNK, Jun NH2-termi- 
nal kinase; TRAF, TNF receptor-associated  factor; VCAM, vascular cell 
adhesion molecule. 
adhesion molecule-1 (VCAM-1; 6, 7), which promotes the 
initial attachment and subsequent firm adhesion of T  lym- 
phocytes and other specialized  effector cells, but not neutro- 
phils  (8, 9).  VCAM-1  expression has also  been associated 
with chronic inflammatory processes such as atherosclerosis 
(10).  Intercellular adhesion molecule-1 (ICAM-1), which is 
constitutively expressed at low levels on HUVECs, can be 
significantly  upregulated by TNF  and  IL-1  (11).  ICAM-t 
can mediate firm adhesion of both neutrophils and T  lym- 
phocytes to endothelium (12), and it also contributes to the 
transmigration  of both  cell types through the  endothelial 
monolayer (13,  14). 
Although E-selectin, VCAM-1,  and  ICAM-1  are each 
induced by TNF and IL-1, the kinetics of their expression 
is different. On HUVECs, E-selectin expression begins at 
1-2 h, peaks at 4 h, and declines to 20% of peak expression 
by 24-48 h. In contrast, VCAM-1 expression begins at 3-4 h, 
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lated thereafter. ICAM-1  expression rises steadily between 
3  and 24 h  and is sustained at peak levels in the presence 
of cytokine for at least 72 h  (11,  15).  The dramatic fall in 
E-selectin occurs in the face of active cytokine and cytokine- 
mediated signaling,  which is necessary to sustain ICAM-1 
expression. Readdition of fresh cytokine does not reinduce 
E-selectin expression. Interestingly, HUVECs treated with 
TNF  can be reinduced  to  express E-selectin by IL-1  and 
vice versa, indicating that downregulation is a form of ho- 
mologous desensitization  (2,  16).  In vivo, the early rise in 
E-selectin correlates with  the  onset  of neutrophil  recruit- 
ment, whereas the later rise in VCAM-1 and ICAM-1 cor- 
relates with the  onset of T  cell recruitment  (17-19).  The 
decline  of E-selectin expression and its  resistance  to  rein- 
duction  may contribute  to  the  changeover from neutro- 
phil- to T cell-rich infiltrates characteristic of antigen-induced 
inflammation in humans (20,  21). 
EC induction of adhesion molecule expression by TNF 
is  transcriptionally  regulated  (22,  23).  Transcription  of 
E-selectin, ICAM-1, and VCAM-1 each depend on activa- 
tion  of NF-KB p50/p65  heterodimers  (22-24).  Although 
NF-KB is necessary for the induction of these three genes, 
there is a significant discrepancy between the kinetics of its 
activation and the  transcription  of E-selectin.  Specifically, 
NF-KB is  activated within  15  min  of cytokine treatment 
and  remains  activated  in  TNF-treated  cells,  showing  no 
significant evidence of decay for at least 24 h  (25),  whereas 
the decline in E-selectin has been associated with a cessation of 
transcription (22) that is not observed in other NF-KB--depen- 
dent responses (e.g., for class I MHC molecules; 25).  The 
discrepancy between NF-v,_B activation and E-selectin ex- 
pression  may be  explained  by the  involvement  of other 
transcriptional regulator elements.  Specifically, the regula- 
tion  of  E-selectin  gene  expression  also  depends  on  a 
cAMP-responsive element  (CRE)-like binding site in the 
E-selectin promoter (22,  26) that is located just upstream of 
three tandem KB-binding sites. By electrophoretic mobility 
shift assay,  this CRE-like site binds at least three different 
nuclear factors in ECs, identified by antibody supershift as 
ATF-2 homodimers, ATF-2/c-Jun heterodimers, and CREB 
proteins (26-28). ATF-2 appears essential for E-selectin ex- 
pression,  since E-selectin,  but not VCAM-1  induction,  is 
inhibited  in  ATF-2  knockout  mice  (29).  TNF  treatment 
increases the relative content ofATF-2/c-Jun heterodimers 
compared to ATF-2 homodimers that bind to the  CRE- 
like element (28),  a change that appears to depend on new 
synthesis of c-Jun (De Luca, L.G., and J.S. Pober, unpub- 
lished observation). Both c-Jun and E-selectin transcription 
in  response to  TNF  may reflect the  activation of one  or 
more Jun-NH2-terminal kinases (JNK), which phosphory- 
late the amino terminus of ATF-2 and c-Jun (30),  thereby 
increasing transactivating potency of these factors (31).  To 
date, however, the role of  JNK activity in E-selectin tran- 
scription has not been directly established. 
VCAM-1  gene  expression  is  mediated  by  binding  of 
p50/p65  heterodimers  to  two  NF-KB  like  binding  sites 
(32).  In addition,  an IRF-l-binding site has been identi- 
fied, just downstream of the KB sites,  which appears to be 
important  for TNF-induced  VCAM-1  expression.  IRF-1 
may cooperate with NF-KB to mediate cytokine-induced 
VCAM-1  expression in ECs  (33),  as was previously dem- 
onstrated for regulation of MHC class I genes (34).  The re- 
quirement for de novo synthesis  of IRF-1  in response to 
TNF  may contribute  to  the  delay  in  onset  of VCAM-1 
transcription compared to E-selectin. 
Recently, we and others have reported that ECs express 
CD40,  and  that  CD40  ligand  can stimulate  HUVECs  to 
express E-selectin,  VCAM-1,  and  ICAM-1  (35-37).  The 
purpose of the present study was to compare CD40 ligand- 
induced  signaling  with  that  initiated  by  cytokines.  Both 
TNF and CD40 ligand activate NF-KB, ATF-2/c-Jun, and 
IRF-1.  Furthermore,  all of the  mediators activate JNK in 
HUVECs.  Moreover,  we  find  that JNK activation,  like 
E-selectin induction, is rapid and transient, shows the same 
rank of order of potency (TNF>  IL-I>>  CD40  ligand) 
and  displays  homologous  desensitization.  These  observa- 
tions  establish  the  similarity of CD40-mediated  signals  to 
those  induced  by cytokines  and  more  directly  implicates 
JNK as a regulator of E-selectin transcription. 
Materials and Methods 
Cytokines and CD40 Ligand Trimer.  Human rTNF was a gift 
of Biogen (Cambridge,  MA).  Human rIL-1 was obtained from 
R  & D Systems, Inc. (Minneapolis, MN). Trimeric recombinant 
murine  or  human  CD40  ligand  was  formed from monomers 
tagged with a leucine zipper tail (38); such preparations of murine 
CD40 ligand trimer have been shown to be biologically active on 
human ceils, delivering stimulatory signals to B cells and EC (35, 
39). All mediators used in this study are flee of detectable  endo- 
toxin by the Limulus assay and heat-inactivation  experiments. 
Monodonal and Polydonal Antibodies.  Murine  mAbs  used as a 
specific antibody for fluorescence flow cytometric analysis of sur- 
face molecules were partly purified from ascites fluid by ammo- 
nium sulfate precipitation  and chromatography on protein G col- 
umns (Pharmacia Biotech,  Inc., Piscataway, NJ). Antibodies used 
in  this  study  were E1/6  (anti-VCAM-1/CD106;  gift from M. 
Bevilacqua, Amgen, Boulder,  CO); K16/16  (nonbinding  IgG1, 
gift from D. Mendrick,  Brigham and Women's Hospital, Boston, 
MA),  and  H4/18  (anti-CD62E,  E-selectin;  IgG1  reference 2]). 
FITC-conjugated mAb anti-ICAM-1/CD54 (clone B-C14; IgG1), 
anti-HLA-dass I ABC (clone B-H9), and isotype control FITC- 
conjugated  IgG1  were  obtained  from Biosource  International 
(Camarillo, CA). 
Rabbit polyclonal IgG used for "supershift" in electrophoretic 
mobility shift  assays were  anti-NF-r,B  p50,  anti-NF-KB  p65, 
anti-c-Rel p75, anti-c-Jun/AP-1 and anti-ATF-2 (obtained from 
Santa Cruz Biotechnology  Inc., Santa Cruz, CA), and anti-CILEB 
(obtained from Upstate Biotechnology,  Inc., Lake Placid, NY). 
Cell Isolation and Culture.  Human ECs were isolated from um- 
bilical  veins  and  cultured  as  previously  described  on  gelatin- 
coated tissue culture plastic (Falcon, Lincoln Park, NJ) (40, 41) in 
Medium  199  containing  20%  FBS  (both  from GIBCO BRL, 
Gaithersburg,  MD), 50 p~g/ml of EC growth factor (Collabora- 
tive Biomedical Products, Bedford, MA), 100 ~Lg/ml porcine he- 
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icillin,  and  100  p,g/ml  streptomycin  (GIBCO  BILL). In  the 
experiments described,  ECs were used at passage 2-4. Such cul- 
tures stain uniformly for yon Willebrand factor and are free of leu- 
kocyte contamination, as judged by the absence of CD45 immun- 
o fluorescence. 
Flow Cytometry.  Cells were suspended for flow cytometry by 
washing monolayers twice with Dulbecco's PBS and incubating 
for 2 min with Trypsin/EDTA (GIBCO BRL). Suspended cells 
were washed once in PBS containing 1% BSA and incubated with 
either unconjugated specific first mAb, diluted 1:200 in PBS/5% 
goat serum, or with FITC-conjugated specific mAb, diluted ac- 
cording to the recommendations provided by the supplier, for 30 
rain at 4~  For indirect immunofluorescence labeling with un- 
conjugated mAb, cells were washed twice with PBS/1% BSA and 
incubated with a secondary  FITC-conjugated F(ab')2 goat  anti- 
mouse IgG (heavy and light chain; Boehringer Mannheim, India- 
napolis, IN) at a 1:50 dilution in PBS/5% goat serum for 30 rain 
at 4~  After indirect or direct immunofluorescence  labeling, cells 
were washed  one time in PBS/1% BSA and two times  in PBS, 
and then fixed with 2% paraformaldehyde  before being analyzed. 
Cells were analyzed by using a FACSort  |  (Becton Dickinson & 
Co., Mountain View, CA) running LYSIS II software. 
Corrected mean fluorescence values were calculated as follows: 
for each treatment, the mean fluorescence  values for the isotype- 
matched control mAb was subtracted from the mean fluorescence 
value for the specific mAb. 
Transient Transfection of HUVECs.  Transient  transfection  of 
HUVECs were performed using a DEAE-dextran protocol (42) 
with E-selectin promoter growth hormone reporter constructs  (a 
gift from T.  Collins, Brigham and Woman's Hospital,  Boston, 
MA; 28).  In brief,  HUVECs were plated  at 50-60% confluence 
on 100-ram tissue culture plates (Falcon) and were washed twice 
with PBS/I  nLM Hepes.  Two ml 1 mM Hepes/PBS containing 
12 gtg DNA and 250/~g/ntl DEAE-dextran (Promega,  Madison, 
WI) were added  to  each  plate,  and cells were incubated for 30 
min at  37~  8  ml of HUVEC growth  media containing 0.08 
mM  chloroquine (Sigma) were  added  to  each  plate,  and cells 
were incubated for another 2.5 h at 37~  The medium was re- 
moved, and the cells were incubated with Medium 199 contain- 
ing 10% FBS and 10% DMSO for 2.5 rain. Cells were then incu- 
bated  overnight in  fresh  HUVEC  growth  media.  After  24  h, 
transfected  cells were  replated  on gelatin-coated 24-well plates 
(Falcon).  48  h  after  transfection,  cells were  treated  with either 
TNF, IL-1, or CD40 ligand .at the indicated concentrations for 
24 h. Supernatants were collected  and assayed for human growth 
hormone  by  radioimmunoassay  (Allegro  HGH  assay system; 
Nichols Institute, San Juan Capistrano, CA). 
Electrophoretic Mobility Shift Assay.  Confluent HUVEC mono- 
layers were either left untreated (control) or treated for 1.5 h with 
either TNF or CD40 ligand with the indicated concentrations. Nu- 
clear extracts were prepared  as described previously (43), normal- 
ized  for  protein concentration, and 4  ~g were  incubated with 
100  ng poly (dl'dC)  (Phamlacia)  for 20  rain at room tempera- 
ture, and then for another 15 min with a 32p-labeled probe in a 
final volume of 15 btl. The probes used were (5'-3'; complement 
sequence  not  shown):  ELAM-I-KB  binding  site:  GCCAT- 
TGGGGATTTCCTCTTT; ELAM-1  CRE-like  binding site: 
GAGACAGAGT'IWCTGACATCATTGTAA;  and ISG15/ISRE 
(IRF-I  binding site):  GATCCTTCAGTTTCGGTTTCCCT- 
TTCCCG. Double-stranded oligonucleotide probe was end-labeled 
with [~-32pIATP (Amersham Life Science, Arlington Heights,  IL) 
using T4 polynucleotide kinase (New England BioLabs, Beverly, 
MA).  Cold  competitor  DNA  at  a  100-fold  excess was  added 
where indicated. For immunochemical identification of nuclear 
factors (antibody "supershift"  analysis), 1 ILl of the indicated anti- 
bodies was incubated with nuclear extracts for 1 h at 4~  before 
the incubation with 32p-labeled probe for  15 rain at room tem- 
perature.  DNA-protein complexes  were resolved  on a 6% non- 
denaturing polyacrylamide  gel containing 7.5% glycerol in 0.25% 
Tris borate-EDTA buffer, pH 8.3 (onefold TBE =  89 mM Tris 
borate, 89 mM boric acid, 20 mM EDTA). Dried gels were ex~ 
posed to x-ray film (Eastman Kodak Co., Rochester, NY) for au- 
toradiography. 
jun NH2-terminal Kinase Assay.  The coding sequence of amino 
acids 1-80 of c-Jun was amplified  from pGEM4c-Jun (gift from 
T. Curran, Roche Research Center, Nutley, NJ; 44)  with two 
primers:  primer  1,  5'-GCGGATCCATGACTGCAA~GATG~ 
GAA-3'; primer 2, 5'-GCAAGCTTGATCAGGCGCTCCCA- 
GCTC-3'. The  PCR  product  was  digested  with  BamHl  and 
HindIII (both from New England BioLabs) and cloned into the 
BamHI and HindIII sites ofpGEX-kg, a GST fusion protein ex- 
pression  vector (45) that was used  to transform  into the DIqSa 
strain of Escherichia coil Protein induction by isopropyl ~-D-thioga- 
lacto-pyraniside  (Sigma) and protein purification was as described 
(46). The amount of purified protein was estimated using the Bio 
Rad (Hercules, CA) protein assay. 
The kinase assay was performed essentially as described by blibi 
et al. (47). Briefly, ECs were cultured in 24-well plates (Falcor0, 
as described  above, and treated  with cytokines as indicated. ECs 
were extracted  with lysis buffer (20 mM Tris-HCl, pH 7.5,  10% 
glycerol,  1% Triton X-100, 0.137  M  NaCI, 20 mM [3-glycero- 
phosphate,  2  mM  EDTA,  1 mi  orthovanadate,  2  mi  pyro- 
phosphate,  10 ~g/ml leupeptin, 1 mM PMSF). The extracts were 
mixed with 10 I.l,1 of glutathione S-transferase (GST)-agarose  sus- 
pension (Sigma) to which 10 ~g of GST-c-Jun (1-80) was added. 
The mixture was rotated at 4~  for 3 li in a microcentrifuge tube 
and  pelleted  by  centrifugation. The  beads  were  washed  three 
times with lysis buffer and once with kinase buffer (20 mM Hepes, 
pH  7.6,  20  mM MgCl2, 25  mM ~-glycerophosphate, 100  }/,M 
sodium orthovanadate, 2  mM DTT, 20  ~M ATP). The kinase 
assay was performed at 25~  for 30 rain by mixing 1 ~  (10 la,  Ci) 
of [,y_32p] ATP with 5 gtl GST-c-Jun (1-80)  agarose suspension 
in kinase buffer. The reactions were terminated by the addition of 
Laemmli  sample buffer (48), and the products were resolved  by 
SDS-PAGE (12.5%). The phosphorylated GST-c-Jun (1-80) was 
visualized  and  quantitated with  a  Phosphorlmager  (Molecular 
Dynamics, Sunnyvale, CA). 
Desensitization Protocol.  Confluent  monolayers  of  HUVECs 
in  12-well  plates  (Falcon)  were either mock pretreated  or pre- 
treated  for 2 d with optimal concentrations of either TNF (100 
U/ml), IL-1 (250 U/ml), or CD40 ligand (10 gtg/ml).  Fresh me- 
dium containing cytokine was added  after 24 h to ensure com- 
plete desensitization.  At the end of the pretreatment period, repli- 
cate  cultures  from  each  group  were  then  mock  treated  or 
cytokine treated  (with TNF, IL-1,  or CD40 ligand) for an addi- 
tional 4 h for  FACS  |  analysis of E-selectin expression  or for an 
additional  15 min for analysis of  JNK activity.  E-selectin expres- 
sion on cytokine-pretreated cells was compared to expression lev- 
els reached  on mock-pretreated cells, and is expressed as the per- 
cent  of inhibition of increase  in  corrected  mean  fluorescence 
intensity (cMFI),  calculated  by  the  following formula:  100  - 
[(cMFI  of treated  cells pretreated  with cytokine A  -  cMFI of 
mock-treated cells pretreated  with cytokine A) /cMFI of treated 
175  Karmann et al. cells mock-pretreated with cytokine] ￿  100, where cytokine A is 
TNF, IL-1, or CD40 ligand as indicated. 
Results 
Activation  of Human  ECs  through CD40  Is  Qualitatively 
Similar to the Activation by TNF or IL- 1.  We have reported 
previously that CD40 ligand binding to CD40 on HUVECs 
upregulates adhesion molecule expression  (35),  and similar 
observations  have  also  been  reported  by  others  (36,  37). 
Here,  we compare endothelial  activation by CD40 ligand 
to that  induced by TNF  and  IL-1. We find,  as  shown in 
Fig.  1,  that  CD40  ligand  induces  the  same  molecules  as 
TNF or IL-1, namely E-selectin, VCAM-1, and ICAM-1, 
with  a  similar  time  course.  Of note,  CD40  ligand,  like 
TNF and IL-1, induces only transient expression of E-selec- 
tin. We have observed a reproducible hierarchy of  potency, 
namely that  induction  by TNF  is  stronger  than  by IL-1, 
which is much stronger than by CD40 ligand at optimally 
effective  concentrations.  No  differences  were  noted  be- 
tween  mouse  and  human  CD40  ligand  preparations  (not 
shown). In the same experiments,  we also examined effects 
on class I MHC molecules. Interestingly, CD40 ligand, like 
IL-1,  is  relatively  ineffective  at  increasing  class  I  MHC 
molecule expression, compared to TNF. 
Activation  of Gene  Transcription in Human EC Transiently 
Transfected with  an  E-Selectin  Promoter Reporter  Gene  Con- 
struct.  IL-1  has  been  shown,  by nuclear  run  off experi- 
ments to induce the transcription of E-selectin in HUVECs 
(22,  23);  we  have  observed  similar  results  with  TNF 
(Palmer-Crocker,  R..,  and J.  S.  Pober,  unpublished  obser- 
vations).  To  analyze  smaller  effects  of CD40  ligand  on 
E-selectin  transcription  and  to  compare  these  effects  with 
IL-1 and TNF, we used transient transfection of HUVECs 
with  an E-selectin  promoter human growth hormone re- 
porter gene construct,  a more sensitive  assay  for transcrip- 
tion. 48 h after transfection, cells were treated for 24 h with 
either  TNF,  IL-1,  or  CD40  ligand  and  accumulation  of 
growth hormone was assayed in the medium. As shown in 
Fig. 2, transfection of a promoterless vector containing the 
growth hormone reporter gene did not result in transcrip- 
tional  activation  when  the  cells  were  treated  with  either 
TNF, IL-1, or CD40 ligand. In contrast, cells that had been 
transfected  with  the  full-length  E-selectin  promoter  re- 
porter gene, showed strong induction (50-fold above back- 
ground) ofgene transcription in response to TNF and IL-1. 
Transcriptional  activation by CD40 ligand was readily de- 
tectable,  about  fivefold above background,  but  was much 
weaker than  the  response  to TNF  and  IL-1. These  results 
reflect the same hierarchy of potency observed for protein 
expression. 
Activation of the Transcription Factors NF-KB, A TF-2 /c-.]un, 
and IRF- 1.  We analyzed the activation by TNF and CD40 
ligand of three transcription factors implicated in the induc- 
tion  of E-selectin,  VCAM-1,  ICAM-1,  and  MHC  class  I 
transcription using electrophoretic mobility shift assays. We 
first investigated the induction of NF-KB, which is impor- 
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Figure  1.  Time dependence of adhesion molecule expression and class 
I MHC molecule expression on HUVECs after treatment with TNF, IL-I, 
or CD40 ligand. Cells were treated for 4, 8, 24, and 48 h with either 
TNF (100 U/ml),  IL-I (250 U/ml),  or CD40 ligand (20 ~g/ml),  and 
were analyzed  by indirect fluorescence flow cytometry for surface expres- 
sion of E-selectin, VCAM-1, ICAM-1, or class 1 MHC molecules. The 
data shown are the corrected mean fluorescence intensities (cMF1), as de- 
scribed in Materials and Methods. Data shown are one of four experi- 
ments with similar results. 
tant for transcriptional activation of all four genes by TNF 
(22, 24, 32, 34, 49-51). We observed (Fig. 3 A) strong ac- 
tivation of NF-KB by CD40 ligand and TNF. Surprisingly, 
no difference in the magnitude of response at optimal me- 
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Figure  2.  Transcriptional  activation  of a  full-length  E-selectin  pro- 
moter reporter gene construct by CD40 hgand, TNF, or IL-1 in HUVECs. 
Cells were transfected  with the filll-length  E-selectin  promoter human 
growth  hormone  construct  or mock transfected  with the promoterless 
growth hormone vector, as described in Material and Methods.  48 h after 
transfection,  cells were left untreated  or treated with either CD40 ligand 
(20 Ixg/ml), TNF (100 U/rrd), or IL-1 (250 U/nil) for 24 h. Accumula- 
tion of human growth hormone was assayed as described in Materials and 
Methods. Data shown are one of three experiments with similar results. 
diator  concentrations  was  evident.  A  supershift  analysis  of 
the  composition  of the  NF-KB  in  the  nucleus  indicated 
that  TNF  and  CD40  ligand  each  primarily  activated  the 
same p50/p65  heterodimeric form of NF-KB. 
We  next investigated the induction of the heterodimeric 
transcription  factor  ATF-2/c-Jun,  which  has  been  shown 
to  be  increased  in  response  to  TNF  in bovine aortic  ECs, 
and which is thought  to participate  in E-selectin transcrip- 
tion  (22,  26-28).  As  shown  in  Fig.  3  B,  both  TNF  and 
CD40  ligand  increased  the  relative quantity  of complex  2 
in HUVECs,  which,  when  analyzed with specific antibod- 
ies  against  c-Jun  and  ATF-2,  is  identified  as  an  ATF-2/ 
c-Jun heterodimer. 
Finally, we  investigated  the  induction  of IRF-1,  a  tran- 
scription factor thought  to be important  for TNF-induced 
upregulation  of VCAM-1  and  class  I  MHC.  We  found 
(Fig. 3  C) that IILF-1 is induced by TNF  and CD40 ligand. 
Again,  the  relative amount  of IRF-1  complex induced  by 
TNF  and CD40 ligand does not appear to be quantitatively 
different. 
Activation of  JNK in HUVECs.  JNK  has been hypothe- 
sized  to  play  a  role  in  transcription  of the  E-selectin  gene 
(22,  26-28)  by  increasing  the  transactivating  potency  of 
ATF-2/c-Jun  heterodimers  (30). As shown in Fig. 4, TNF, 
IL-1 and CD40 ligand all activate JNK  in EC, measured by 
phosphorylation  of c-Jun  1-80.  Activation is minimal after 
Figure 3.  CD40 ligand and TNF activate transcription  factors NF-KB, 
C-Jun/ATF-2, and IRF-1 in HUVECs.  (A) Nuclear extracts were pre- 
pared from cells either left untreated  or treated  for 1 h and 30 rain with 
either TNF  (100 U/ml)  or  CD40  ligand  (5  ~g/ml).  Nuclear extracts 
were either preincubated  with specific antibodies to p50, p65, or c-rel or 
with polyclonal rabbit serum at 1 ~g/sample for 45 min, before addition 
of the E-selectin  NF-KB sequence for 20 min before  electrophoresis.  (B) 
Nuclear extracts were prepared  from cells treated as described in A, and 
incubated  with antibodies  to c-Jun,  ATF-2 and CREB, or rabbit serum 
for 1 h, followed by the addition  of the E-selectin  CRE/ATF sequence 
for 20  min before  electrophoresis.  (C)  Nuclear extracts  were prepared 
from cells treated as described in A, and either preincubated  with specific 
cold competitor (ISG15/ISRE) or nonspecific cold competitor (E-selectin 
NFotd3) for  15  rain  were  indicated,  followed by  the  addition  of the 
ISG15/ISRE sequence  15 rain  before  electrophoresis.  The band  identi- 
fied as IRF-1 was identified by supershift in two other experiments  (not 
shown).  Results  shown in  the figure are representative  of three  experi- 
ments. 
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CD40 ligand. HUVECs were treated with TNF (10 U/nil).  IL-1 (I(X) 
U/ml),  and CD40 ligand (10 Izg/ml) for 5,  15, and 30 n'an. HUVECs 
were cultured without cytokines  as a control. JNK activity was measured 
as described in Materials and Methods. The results shown are representa- 
tive of  three similar experiments. 
5 min of treatment.  Peak levels are reached at 15 min, with 
a slight decrease of activity after 30 min. By 48 h, JNK ac- 
tivity is only 20% or less  of peak levels (Fig.  5).  The time 
course of  JNK activation appears similar for all three agents, 
but  there  is a  significant difference  in  the  level  of activity 
induced  by each  cytokine.  The  highest  activity was  mea- 
sured  with  TNF,  slightly  lower  activation  levels  were 
reached by  IL-1, and JNK was activated to  a  much  lesser 
degree by CD40 ligand. Measures of  JNK activity obtained 
by quantitating  phosphorylation  of c-Jun(1-80)  at a  single 
time point,  however, may not give an accurate measure  of 
active  enzyme.  Nevertheless,  the  relative  levels  of activity 
are  consistent  with  the  hierarchy  of potency  observed for 
E-selectin transcription and expression. 
Homologous  Desensitization  of  E-Selectin  Expression and 
JNK Activation.  We  have  previously  described  the  phe- 
nomenon  of homologous  desensitization  in  response  to 
TNF or IL-1  in  the induction of E-selectin expression  on 
ECs  (2,  16,  52).  Specifically,  after  24--48  h  of cytokine 
treatment,  E-selectin  expression  is  decreased  to  "~  of 
peak  expression  and retreatment  of EC with  the same  cy- 
tokine results in only minimal reinduction of E-selectin ex- 
pression.  This  desensitization  is  homologous because  cells 
respond fully to treatment with a different cytokine. Here, 
we have extended  this  analysis to CD40 ligand.  As shown 
in Table  1, expression of E-selectin was significandy inhib- 
ited when  cells pretreated  with  CD40 ligand were  rechal- 
lenged  with  CD40  ligand,  but  not  when  the  same  cells 
were  rechallenged  with  TNF  or IL-I. Similarly,  cells  de- 
sensitized to TNF or IL-I for 48 h were fully responsive to 
E-selectin  reinduction  in  response  to  CD40  ligand.  Thus, 
CD40 ligand also shows homologous desensitization. 
Finally,  we analyzed reactivation  of  JNK in response  to 
TNF, IL-1, and CD40 ligand. The results, shown in Fig. 5, 
suggest  that JNK  activity  also  undergoes  homologous de- 
sensitization.  Specifically, cells  pretreated  with TNF,  IL-1, 
or CD40 ligand showed blunted reactivation of  JNK when 
retreated  with  the same agents  (i.e.,  compare lanes  2  with 
6,  3 with  11, and 4 with  16),  and were preferentially reac- 
tivated  by either  of the  other  agents.  Of note,  IL-l-pre- 
treated cells  also showed a small degree of heterologous de- 
sensitization  to  TNF  and  CD40  ligand.  Again,  we  point 
out that such  assays  may not quantitatively  reflect enzyme 
activity.  However,  the  experimental  results  do  convinc- 
ingly  demonstrate  homologous  desensitization  of this  en- 
zyme in HUVECs. 
Discussion 
We  have  reported  here  qualitatively  similar  patterns  of 
activation of HUVECs in response to the inflammatory cy- 
tokines  TNF and  IL-1 with  the  response to the ligand for 
CD40.  We  find  upregulation  and  induction  of the  adhe- 
sion molecules E-selectin, VCAM-1, and ICAM-1, as well 
as class I MHC molecules on the EC surface. Although the 
time course of expression was similar, the magnitude of ex- 
pression observed with the three activators was very differ- 
ent. The responses showed a consistent hierarchy in which 
TNF is slightly better than  IL-1, and both are much more 
effective than CD40 ligand. The actions of all three media- 
tors on E-selectin  expression  appear to be transcriptionally 
regulated, as shown by transient transfection assays using an 
E-selectin  promoter  reporter  gene.  The  analysis  of tran- 
scription  factors  by  electrophoretic  mobility  shift  assays 
shows activation  of NF-r,B,  ATF-2/c-Jun,  and  IILF-1 by 
TNF and CD40 ligand. TNF, IL-1, and CD40 ligand rap- 
idly  and  transiently  activate JNK  in  HUVECs.  All  three 
agents  display  homologous  desensitization  for reinduction 
of E-selectin expression and for the activation of  JNK. 
In several  assays,  we  have  noted  that  EC  are  less  effec- 
tively activated by CD40 ligand than  by TNF  or IL-1.  In 
the experiments reported here, we have used an optimal or 
Figure 5.  Homologous desen- 
sitization  of  JNK  activity,  in 
HUVECs  by  TNF,  IL-1, and 
CD40  ligand. Cells were pre- 
treated for 48 h and treated for 
15 rain, as described in Materials 
and  Methods. with TNF  (100 
U/ml),  IL-I  (250 U/ml),  and 
CD40  ligand (10  Ixg/ml), and 
JNK  activity was  measured  as 
described in Materials and Methods. The results shown are representative of  two similar experiments, both of  which were performed in rephcate culture; 
of cells assayed  for E-selectin surface expression, as presented in Table l. 
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Expression by CD40 Ligand, TNF-ot, and IL- la 
Percent of inhibition after 
treatment 
CD40 
Pretreatment*  TNF  IL-1  ligand 
TNF (100 U/ml)  91.0'  None  None 
IL-1 (250 U/ml)  None  93.5  None 
CD40 ligand (10 ~g/ml)  None  None  78.0 
*EC were mock-pretreated  or pretreated for 44 h with the indicated 
agents, as described in Materials and Methods.  At this time,  the ECs 
were treated for 4 h either with no cytokine, with the same agent, or 
with one of the other agents as indicated. 
*The values show the percent of inhibition of the increase in mean flu- 
orescence intensities ofpretreated cells compared to the cells that were 
not pretreated, as described in Materials and Methods. 
The results shown here are representative of five experiments with sim- 
ilar results 
near optimal concentration  of soluble CD40 ligand trimer, 
but  we  have never approached  the  level of response  seen 
with TNF and IL-1. We are reluctant to overinterpret this 
difference because it may reflect the fact that we used a sol- 
uble form of CD40 ligand, whereas this molecule normally 
acts as a cell surface ligand expressed on activated CD4 + T 
cells  (39,  53,  54).  Cell-cell  interactions  may  be  a  much 
more  efficient  means  of dehvering  a  signal  by this  mole- 
cule.  In support of this  idea,  it has been recently reported 
that TNF-RII  can be activated  much more  effectively by 
membrane-bound TNF than by soluble TNF  (55). 
Signal  transduction  pathways  activated  by  TNF,  IL-1, 
and CD40  are under intense investigation in many labora- 
tories.  Recent studies using molecular cloning with a yeast 
two-hybrid  system have identified  "adapter proteins"  that 
associate with TNF receptors and are directly or indirectly 
involved in  coupling  receptors  to responses  (56-59).  Spe- 
cifically, TNF-R.I interacts with a protein, called the TNF- 
RI-associated  death  domain  protein  (TRADD),  whereas 
TNF-RII  interacts with at least two separate adapter mole- 
cules,  called  TNF  receptor-associated  factor  1  (TRAF1) 
and TRAF2.  In HUVECs, NF-~d3 activation and gene ex- 
pression  is  mediated  largely  or  entirely  through  TNF-RI 
and not through TNF-RII  (15, 60). Paradoxically, TRAF2 
has been implicated as the adapter protein linked to NF-KB 
activation.  The explanation for this seeming discrepancy is 
that TRAF2  appears to be involved in TNF-RI-mediated 
signaling  by indirect  association  via TRADD.  A  member 
of  the  same  family  of molecules  as  the  TKAFs,  called 
CD40-associated  factor 1  (CRAF1,  also called TRAF3),  is 
associated with the intracellular domain of CD40 in B  cells 
(61, 62). The function of TRAF3 is not known, but CD40 
can also associate with TR_AF2  (59),  thereby coupling  this 
receptor to NF-KB  activation.  HUVECs  express IL-1-R.I, 
the signaling receptor for this  cytokine  (63-65).  Recently, 
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a kinase has been identified which is associated with the IL-1 
RI, called IRAK (66), and functional analysis has suggested 
that IRAK activation by IL-1 leads to NF-KB activation.  It 
should be noted that neither TRAF2 nor IRAK have been 
reported in HUVECs as of yet, and the signal transduction 
pathway  by which  either  adapter  molecule  is  coupled  to 
NF-KB is still unknown. 
TNF and IL-1 can both activate JNK in a variety of cells 
(31,  67).  To the  best of our knowledge,  this  pathway has 
not  been  previously  reported  in  HUVECs.  More  signifi- 
cantly, we have presented here several findings that strongly 
suggest direct involvement of  JNK in E-selectin gene regu- 
lation.  We have shown that JNK in HUVECs  is activated 
by CD40  ligand,  TNF,  and  IL-1;  that JNK  activation by 
these  mediators,  hke  E-selectin  expression,  is  rapid  and 
transient;  and  that  activation  of JNK  shows  homologous 
desensitization,  a phenomenon  that has been also observed 
for E selectin surface expression. We presume thatJNK acts 
on the ATF-2/c-Jun  heterodimeric factor that binds to the 
E-selectin C1LE-like element. 
The mechanism of homologous desensitization of E-selec- 
tin reinduction has not been identified, but two possibilities 
can be ruled out. First, the mechanism does not involve re- 
ceptor inactivation  or downregulation,  since  sustained  ac- 
tive cytokine  is required  for persistent  expression  of other 
molecules (e.g., ICAM-1)  at times when HUVECs are ho- 
mologously desensitized.  Second,  NF-KB inactivation does 
not seem to be responsible for homologous desensitization, 
since this  factor remains activated even after 24 h  of TNF 
treatment (25). The new studies reported here strongly im- 
plicate homologous  desensitization  of JNK as the basis for 
homologous  desensitization  of E-selectin reinduction.  The 
fact that desensitization  is homologous may be biologically 
significant because it would allow events that occur at dif- 
ferent times during inflammation, such as CD4 + T  cell ac- 
tivation  and  cytokine  production,  to  reinduce  or  sustain 
E-selectin expression, leading to prolonged inflammation. 
The molecular basis of  JNK desensitization is not known. 
Since all three receptors activate JNK and show desensitiza- 
tion to their ligand,  one possibility is that a receptor-bound 
adapter protein,  such as a TRAF  or a G  protein that is di- 
rectly associated with the receptor, becomes inactivated af- 
ter  transducing  a  signal  that  leads  to  activation  of JNK. 
Since the  adapter molecule inactivating  this pathway is re- 
ceptor associated, desensitization would be expected to oc- 
cur in a ligand-specific manner.  Separate pools of the same 
adapter  protein  could  be  involved  for all  three  receptors, 
thereby providing a  means  of restimulation  in response to 
heterologous signals. 
Finally,  our  observations  have  potential  clinical  rele- 
vance.  New  antiinflammatory  therapies  have  been  pro- 
posed to target the function of endothelial leukocyte adhe- 
sion molecules,  such  as E-selectin.  An  alternative  target is 
the prevention  of adhesion  molecule "expression.  A  poten- 
tial problem with this approach is that proinflammatory sig- 
nals are redundant  and an agent that blocks TNF may not 
be  effective  because  IL-1  or  contact-dependent  signals 
(e.g.,  such  as  those  mediated by CD40  ligand)  can bypass the blockade. Our data suggest there are contact-dependent 
pathways that converge with TNF and IL-1 signals to acti- 
vate ECs,  providing common downstream targets. NF-KB 
has been potentially identified as such a target, but this has a 
major  drawback,  namely  that  TNF-induced  ceil  death, 
which  is independent  of NF-KB  (56,  57),  may in  fact be 
limited by NF-~B-induced genes  (68-70).  Our  new  data 
support the idea that JNK may be an alternative, more se- 
lective target,  which may have  the  advantage of targeting 
tissue factor as well as E-selectin, another endothelial gene 
that  shows  rapid and  transient induction  followed by ho- 
mologous  desensitization  (71).  We  do  not  as  yet  know 
which JNK  isoform is most relevant for E-selectin induc- 
tion,  but  answers  to  these  and  other  related  questions 
should be forthcoming in the near future. 
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